نتایج جستجو برای: گیرنده her2

تعداد نتایج: 20398  

Journal: :Cancer research 2007
Nabil Ahmed Maheshika Ratnayake Barbara Savoldo Laszlo Perlaky Gianpietro Dotti Winfried S Wels Meenakshi B Bhattacharjee Richard J Gilbertson H David Shine Heidi L Weiss Cliona M Rooney Helen E Heslop Stephen Gottschalk

Medulloblastoma is a common malignant brain tumor of childhood. Human epidermal growth factor receptor 2 (HER2) is expressed by 40% of medulloblastomas and is a risk factor for poor outcome with current aggressive multimodal therapy. In contrast to breast cancer, HER2 is expressed only at low levels in medulloblastomas, rendering monoclonal antibodies ineffective. We determined if T cells graft...

2016
Nick Beije Wendy Onstenk Jaco Kraan Anieta M. Sieuwerts Paul Hamberg Luc Y. Dirix Anja Brouwer Felix E. de Jongh Agnes Jager Caroline M. Seynaeve Ngoc M. Van John A. Foekens John W.M. Martens Stefan Sleijfer

BACKGROUND Preclinical and clinical studies have reported that human epidermal growth factor receptor 2 (HER2) overexpression yields resistance to endocrine therapies. Here the prevalence and prognostic impact of HER2-positive circulating tumor cells (CTCs) were investigated retrospectively in metastatic breast cancer (MBC) patients with a HER2-negative primary tumor receiving endocrine therapy...

2014
Adam M Brufsky

Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall survival in adjuvant and first-line settings. However, a large proportion of patients with breast ...

Journal: :Cancer research 2014
Teemu T Junttila Ji Li Jennifer Johnston Maria Hristopoulos Robyn Clark Diego Ellerman Bu-Er Wang Yijin Li Mary Mathieu Guangmin Li Judy Young Elizabeth Luis Gail Lewis Phillips Eric Stefanich Christoph Spiess Andrew Polson Bryan Irving Justin M Scheer Melissa R Junttila Mark S Dennis Robert Kelley Klara Totpal Allen Ebens

Clinical results from the latest strategies for T-cell activation in cancer have fired interest in combination immunotherapies that can fully engage T-cell immunity. In this study, we describe a trastuzumab-based bispecific antibody, HER2-TDB, which targets HER2 and conditionally activates T cells. HER2-TDB specifically killed HER2-expressing cancer cells at low picomolar concentrations. Becaus...

Journal: :iranian journal of immunology 0
seyyed mohammad ali ghayumi department of internal medicine kambiz aghasadeghi department of internal medicine mehrnoosh dorouchi department of immunology abbas ghaderi department of immunology

background: the her-2/neu gene is located on chromosome 17q21 and encodes a 185-kda transmembrane glycoprotein with tyrosine kinase activity reported to be released in soluble form in various malignancies. objective: to evaluate the clinical significance of soluble her-2/neu as a diagnostic marker in lung cancer. methods: serum levels of soluble her-2/neu were measured in 43 patients with lung ...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه زابل - دانشکده علوم پایه 1392

سرطان پستان، شایع ترین سرطان در بین زنان و دومین عامل مرگ و میر بعد از سرطان ریه می باشد. این سرطان 32% کل سرطان های زنان را تشکیل می دهد. در کنار تغییرات ژنتیکی متعدد شناخته شده، تغییرات اپی ژنتیکی متعددی کشف شده اند که در فرایند تومورزایی در بافت پستان دخیلند و به تغییر پایدار در الگوی بیان ژن ها در سلول ها منجر و باعث ایجاد و پیشرفت بدخیمی می شوند. پروتوانکوژن her2 پروتئینی را رمزگذاری می کن...

2012
Lina Ekerljung Johan Lennartsson Lars Gedda

We have previously shown that the HER2-specific affibody molecule (Z(HER2∶342))₂ inhibits proliferation of SKBR-3 cells. Here, we continue to investigate its biological effects in vitro by studying receptor dimerization and clonogenic survival following irradiation. We found that (Z(HER2∶342))₂ sensitizes the HER2-overexpressing cell line SKBR-3 to ionizing radiation. The survival after exposur...

Journal: :Cancer research 2000
H Roh J Pippin J A Drebin

The HER2/neu oncogene is overexpressed in a significant fraction of human tumors; such overexpression is thought to play a role in the aberrant proliferation of cancer cells. The effects of HER2/neu-specific phosphorothioate antisense oligodeoxyribonucleotides on HER2/neu expression, tumor cell proliferation, and activation of apoptotic cell death pathways have been examined. Antisense treatmen...

Journal: :Journal of clinical pathology 2015
Laura J Tafe Heather B Steinmetz Samantha F Allen Betty J Dokus Gregory J Tsongalis

Evaluation of HER2 (ERBB2) gene amplification or protein expression is standard of care in breast (BR) and advanced stage gastro-oesophageal cancers to identify patients eligible for anti-HER2 therapies. Here, we evaluate a rapid fluorescence in situ hybridisation (FISH) technology (HER2 instant quality (IQ) FISH pharmDx Kit) for detection of HER2 in patients with BR and gastro-oesophageal canc...

Journal: :International journal of oncology 2009
Richard E Francis Stephen S Myatt Janna Krol Johan Hartman Barrie Peck Ursula B McGovern Jun Wang Stephanie K Guest Aleksandra Filipovic Ondrej Gojis Carlo Palmieri David Peston Sami Shousha Qunyan Yu Piotr Sicinski R Charles Coombes Eric W-F Lam

The tyrosine kinase receptor, HER2 is a crucial prognostic marker and therapeutic target for breast cancer; however, the downstream targets and biological effectors of HER2 remain unclear. We investigated the relationship between HER2 and the transcription factor FoxM1 in breast cancer. HER2 and FoxM1 expression levels were compared in breast carcinoma cell lines, paraffin-embedded breast cance...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید